FDA
1
Overview of Postmarketing Safety Surveillance in FDA 
(For Drugs and Biologics)
n Min Chen, M.S., R.Ph.
nAssociate Director
nDivision of Drug Risk Evaluation
nOffice of Drug Safety
nCDER